Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Equity (2016 - 2025)

Karyopharm Therapeutics' Return on Equity history spans 13 years, with the latest figure at 0.01% for Q4 2025.

  • For Q4 2025, Return on Equity fell 43.0% year-over-year to 0.01%; the TTM value through Dec 2025 reached 0.01%, down 43.0%, while the annual FY2025 figure was 0.02%, 46.0% down from the prior year.
  • Return on Equity reached 0.01% in Q4 2025 per KPTI's latest filing, down from 0.49% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 5.11% in Q1 2023 to a low of 30.01% in Q1 2021.
  • Average Return on Equity over 5 years is 0.51%, with a median of 0.52% recorded in 2025.
  • Peak YoY movement for Return on Equity: plummeted -2829bps in 2021, then surged 3097bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.91% in 2021, then surged by 130bps to 2.11% in 2022, then crashed by -100bps to 0.0% in 2023, then surged by 68801bps to 0.44% in 2024, then crashed by -97bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Return on Equity are 0.01% (Q4 2025), 0.49% (Q3 2025), and 0.56% (Q2 2025).